Researchers from University of Florence Report Details of New Studies and Findings in the Area of Headache (Outcomes, Unmet Needs, and Challenges In the Management of Patients Who Withdraw From Anti-cgrp Monoclonal Antibodies: a Prospective...).

Researchers from the University of Florence conducted a study on patients who discontinued treatment with anti-CGRP monoclonal antibodies for migraine. The study found that about 25% of patients failed to respond to the treatment, leading to discontinuation. The majority of patients discontinued due to ineffectiveness, with 77.9% ceasing treatment within the first year. Further research is needed to identify non-responder features and address unmet needs in migraine treatment. [Extracted from the article]